Recent advances in biotechnology and genetic engineering have produced new therapeutics and treatment modalities for many diseases and created an emphasis on effectively delivering novel drugs to their target destinations. RNA-based therapeutics are poised to revolutionize treatment options for a variety of genetic diseases that had until recently been untreatable. However, delivering fragile therapeutic RNA to cellular and subcellular targets remains daunting.